Commentary|Podcasts|February 18, 2025

Navigating Distrust: Pharma in the Age of Social Media

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

In this episode of the Pharmaceutical Executive Podcast, CEO and Founder of Sooth, Ian Baer, is back to discuss:

Related to this article

October 22nd, 2026

Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.

October 22nd, 2026

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy

FDA has granted accelerated approval to Ultomiris based on Phase III data showing a 43.4% placebo-adjusted reduction at 34 weeks.

The FDA cleared GSK’s bepirovirsen as add-on therapy for chronic hepatitis B, based on phase 3 trials in which 19% of patients reached functional cure. Credit: Stock.Adobe.com/Destina

October 21st, 2026

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure.

October 20th, 2026

Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli

METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.

Accelerated approval puts biomarker testing at diagnosis in focus as GSK’s PD-1 inhibitor enters rectal cancer. Credit: Stock.Adobe.com/Sebastian Kaulitzki

October 19th, 2026

FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer

FDA’s conditional approval of Jemperli (dostarlimab-gxly) rests on a single-arm phase 2 trial, with independent-review data still maturing.

FDA’s approval of satralizumab rests on two phase 3 trials with divergent results and offers every-four-week dosing after a loading period.

October 16th, 2026

FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease

The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.

October 14th, 2026

FDA Launches Rare Disease Framework Initiative

FDA is launching the Rare Disease Framework Initiative, aiming to tailor drug development and review requirements to the realities of small patient populations.

October 21st, 2026

Pharmaceutical Executive Daily: FDA Approves Hibsago

A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.